Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Xin ChenNorhan AmarYuankui ZhuChunguang WangChunjiao XiaXiaoqing YangDongde WuMingqian FengPublished in: Journal for immunotherapy of cancer (2021)
Our results demonstrated that DLL3-targeted bispecific antibody plus PD-1 inhibition was effective in controlling SCLC growth.
Keyphrases